title: Maculopapular rash in the convalescent phase of Kawasaki disease: case series and literature review.
abstract: Intravenous immunoglobulin (IVIG) is currently the standard treatment for Kawasaki disease (KD). Although IVIG therapy is generally well tolerated, several minor adverse reactions have been reported. We report a patient with KD treated with IVIG, who developed a cutaneous reaction in the convalescent phase (approximately 10 days after therapy). We identified seven additional KD cases with a similar presentation, accounting for 9.3 % of KD patients at our hospital. We performed a literature review and found that a maculopapular rash could be observed approximately 10 days after IVIG treatment, in patients with and those without KD.
  
  
  CONCLUSIONS
  Maculopapular rash can occur in nearly 10 % of IVIG-treated children with KD in our cohort, approximately 10 days after treatment. A delayed-onset adverse event of IVIG could be a causative etiology of this unrecognized eruption.
authors.affiliation: Department of Pediatrics, Chigasaki Municipal Hospital, Honson 5-15-1, Chigasaki, Kanagawa, Japan. masatotakeuchi@gmail.com
authors.forename: Masato
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Oda
authors.forename: Isao
authors.initials: I
authors.lastname: Suzuki
mesh_terms: D002675:Child, Preschool; D003289:Convalescence; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors